CS Capital

Lingmo Medical is a company that provides department-level flexible endoscopic solutions.It is advancing the development of flexible endoscopy and providing higher-quality endoscopic solutions for clinicians and patients, allowing more risk categories to benefit from it. Benefit from endoscopic diagnosis and treatment.

Hengyu Biotechnology is a specialized provider of biological testing services aimed at drug developers. Founded by a scientific research team, the company focuses on delivering comprehensive biosafety testing solutions for innovative pharmaceutical companies worldwide. Its services include viral clearance process validation, cell bank validation, replicative virus testing, batch release testing, CGT bioanalysis, and process residue testing. These offerings are designed to meet regulatory filing requirements across the United States, China, and Europe, supporting the entire life cycle of biologics from research and development to marketing.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers comprehensive contract research organization (CRO) services. The company aims to expedite the antibody discovery process by providing a one-stop solution for antibody development. Biointron utilizes advanced technologies, including rapid expression platforms, antibody sequencing, and labeling tools, to achieve high-throughput recombinant antibody production. Its commitment to delivering high-quality and cost-effective recombinant protein and antibody reagents positions Biointron as a significant player in the biotechnology sector, catering to the needs of researchers and organizations in the field.

Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression in mammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Hengyu Biotechnology is a specialized provider of biological testing services aimed at drug developers. Founded by a scientific research team, the company focuses on delivering comprehensive biosafety testing solutions for innovative pharmaceutical companies worldwide. Its services include viral clearance process validation, cell bank validation, replicative virus testing, batch release testing, CGT bioanalysis, and process residue testing. These offerings are designed to meet regulatory filing requirements across the United States, China, and Europe, supporting the entire life cycle of biologics from research and development to marketing.

Future Vision is a visual health service organization based in Shanghai, specializing in the prevention and control of myopia, amblyopia rehabilitation training, and medical optometry for children aged 3 to 16. The company utilizes advanced North American optometry technology to deliver its services, aiming to address the growing concerns of visual health among children. By focusing on early intervention and comprehensive eye care, Future Vision seeks to improve the visual outcomes for its young clientele.

Laekna Therapeutics is a clinical‑stage biotechnology company that develops novel therapies for oncology and liver disease. The company has built a comprehensive research and development platform that moves molecules from discovery to registration‑ready trials. It has initiated six clinical studies, including three multi‑regional trials targeting standard‑of‑care resistant cancers. Its lead product candidates are LAE002, an ATP‑competitive AKT inhibitor for ovarian cancer, and LAE001, a therapeutic agent for liver disease. Laekna also maintains a broader pipeline of 14 additional candidates.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, leveraging a deep understanding of disease biology and pharmacology to address various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed aims to provide healthcare professionals with more effective treatment options by building a robust translational platform that integrates advanced expertise and efficient execution capabilities in drug development.

G7 is a company that specializes in fleet management systems aimed at optimizing the transportation ecosystem. With a significant installation base of 800,000 cargo vehicles across China, G7 utilizes proprietary hardware devices to gather and analyze data for logistics companies and drivers. The company's platform enables businesses to locate and monitor transportation vehicles, track driver behaviors, and estimate departure and arrival times. Additionally, G7 provides detailed insights on route optimization, fuel consumption, and cargo conditions, such as temperature and humidity, which helps corporate clients and business owners enhance the efficiency of their transportation networks.

Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe, underserved diseases. Led by experienced pharmaceutical executives, the company employs three distinct research and development platforms: TavoSelect, an innovative phage display library; TavoPrecise, a platform for engineering tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. Tavotek's pipeline includes various product candidates targeting cancers, autoimmune conditions, and infectious diseases.

Biointron, founded in 2012 and based in Shanghai, China, specializes in the development of recombinant antibody technology and offers comprehensive contract research organization (CRO) services. The company aims to expedite the antibody discovery process by providing a one-stop solution for antibody development. Biointron utilizes advanced technologies, including rapid expression platforms, antibody sequencing, and labeling tools, to achieve high-throughput recombinant antibody production. Its commitment to delivering high-quality and cost-effective recombinant protein and antibody reagents positions Biointron as a significant player in the biotechnology sector, catering to the needs of researchers and organizations in the field.

Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents.

Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines.

Cipher Gene Tech is a biomedical data analysis and interpretation platform specializing in genetic analysis, particularly in the realm of childhood genetic diseases. The company integrates various technical disciplines, including bioinformatics, molecular and medical genetics, and statistics, to provide precise and efficient interpretation of diverse bio-mic data such as genomics and transcriptomics. Through collaborations with clinical laboratories, Cipher Gene enhances the practice of precision medicine and supports scientific research and personalized studies. The company is committed to developing its own biomedical database and an AI-based data analysis platform, facilitating professional information sharing and enabling physicians to make accurate treatment decisions effectively.

Beijing Tuo Rui Detection Technology Co., Ltd., founded in 2013 and based in China, specializes in the research, development, and production of diagnostic and testing products for animal health. The company focuses on medical equipment for pets and other animals, offering a range of testing solutions that include biochemical, routine, genetic, immunological, and microbiological testing. By providing advanced diagnostic tools, Beijing Tuo Rui Detection Technology aims to enhance medical diagnosis and therapy for animals, ensuring better health management and care for pets.